|Bid||4.32 x 3000|
|Ask||6.00 x 2200|
|Day's Range||4.7195 - 4.8900|
|52 Week Range||3.3200 - 17.3500|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The big shareholder groups in TG Therapeutics, Inc. (NASDAQ:TGTX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...
Historically, biotech companies have offered investors the possibility of outsized success, but they also carry high levels of risk. The reason for this is that biotech companies traditionally race to develop cutting edge products. When a product in a biotech company's pipeline fails to materialize or to produce the desired results, that company's stock price can suffer the consequences.
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
In 2011 Mike Weiss was appointed CEO of TG Therapeutics Inc (NASDAQ:TGTX). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
On GW Pharmaceuticals' (GWPH) fourth-quarter conference call, investor focus will be on the company's launch and commercialization plans for its newly approved anti-epileptic drug Epidiolex.
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 21.82% and -5.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the New York-based company said it had a loss of 43 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These three biotechs will soon present clinical trial results that could send their share prices screaming in one direction or the other.
As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...
If you own shares in TG Therapeutics Inc (NASDAQ:TGTX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
Today, TG Therapeutics stock is trading at a price of $5.82, which is ~37.0% down from yesterday’s closing price of $9.25. The stock also hit a 52-week low of $5.70. TG Therapeutics had hit a 52-week high of $17.35 on March 9. Reason for the decline